SE9700134D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9700134D0
SE9700134D0 SE9700134A SE9700134A SE9700134D0 SE 9700134 D0 SE9700134 D0 SE 9700134D0 SE 9700134 A SE9700134 A SE 9700134A SE 9700134 A SE9700134 A SE 9700134A SE 9700134 D0 SE9700134 D0 SE 9700134D0
Authority
SE
Sweden
Prior art keywords
new formulation
formulation
formoterol
useful
treatment
Prior art date
Application number
SE9700134A
Other languages
English (en)
Swedish (sv)
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9700134(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9700134A priority Critical patent/SE9700134D0/xx
Publication of SE9700134D0 publication Critical patent/SE9700134D0/xx
Priority to US09/005,306 priority patent/US5983956A/en
Priority to AT98901617T priority patent/ATE257699T1/de
Priority to HU0000843A priority patent/HU228682B1/hu
Priority to NL1008021A priority patent/NL1008021C2/nl
Priority to RU99118588/14A priority patent/RU2180220C2/ru
Priority to IL13083798A priority patent/IL130837A0/xx
Priority to SK958-99A priority patent/SK283949B6/sk
Priority to PCT/SE1998/000039 priority patent/WO1998031351A1/en
Priority to UA99074043A priority patent/UA57763C2/uk
Priority to JP53421798A priority patent/JP4512203B2/ja
Priority to IDW990665A priority patent/ID21917A/id
Priority to AU57858/98A priority patent/AU728835B2/en
Priority to EEP199900294A priority patent/EE04038B1/xx
Priority to IL16286498A priority patent/IL162864A/xx
Priority to TR1999/01692T priority patent/TR199901692T2/xx
Priority to ES98901617T priority patent/ES2212262T3/es
Priority to SI9830606T priority patent/SI1009394T1/xx
Priority to EP98901617A priority patent/EP1009394B1/en
Priority to CNB988018993A priority patent/CN1213741C/zh
Priority to DE69821119T priority patent/DE69821119T2/de
Priority to NZ336593A priority patent/NZ336593A/xx
Priority to KR10-1999-7006413A priority patent/KR100528417B1/ko
Priority to PT98901617T priority patent/PT1009394E/pt
Priority to CZ19992556A priority patent/CZ295682B6/cs
Priority to CA002277890A priority patent/CA2277890C/en
Priority to PL98334528A priority patent/PL189552B1/pl
Priority to DK98901617T priority patent/DK1009394T3/da
Priority to BR9806895-4A priority patent/BR9806895A/pt
Priority to GR980100022A priority patent/GR980100022A/el
Priority to BE9800031A priority patent/BE1011401A3/fr
Priority to IE980025A priority patent/IE980025A1/en
Priority to FR9800459A priority patent/FR2759907B1/fr
Priority to ES009800079A priority patent/ES2149082B1/es
Priority to IS5109A priority patent/IS2243B/is
Priority to NO19993538A priority patent/NO327457B1/no
Priority to US09/401,592 priority patent/US6199607B1/en
Priority to JP2009255061A priority patent/JP2010059180A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9700134A 1994-10-03 1997-01-20 New formulation SE9700134D0 (sv)

Priority Applications (38)

Application Number Priority Date Filing Date Title
SE9700134A SE9700134D0 (sv) 1997-01-20 1997-01-20 New formulation
US09/005,306 US5983956A (en) 1994-10-03 1998-01-09 Formulation for inhalation
DK98901617T DK1009394T3 (da) 1997-01-20 1998-01-13 Ny formulering til inhalering med en ihældt bulkdensitet på fra 0,28 til 0,38 g/ml omfattende formoterol
BR9806895-4A BR9806895A (pt) 1997-01-20 1998-01-13 Nova formulação; apresentando densidade volumétrica, quanto derramada, de 0,20 a 038 g/ml, compreendendo formoterol
SI9830606T SI1009394T1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
CNB988018993A CN1213741C (zh) 1997-01-20 1998-01-13 注入堆积密度为0.28～0.38g/ml的含福莫特罗的吸入用新配方
NL1008021A NL1008021C2 (nl) 1997-01-20 1998-01-13 Nieuwe formulering voor inhalatie.
RU99118588/14A RU2180220C2 (ru) 1997-01-20 1998-01-13 Препарат для ингаляции, имеющий насыпную объемную плотность от 0,28 до 0,38 г/мл, содержащий формотерол
IL13083798A IL130837A0 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml comprising formoterol
SK958-99A SK283949B6 (sk) 1997-01-20 1998-01-13 Inhalačná kompozícia, spôsob jej prípravy a jej použitie na prípravu liečiva
PCT/SE1998/000039 WO1998031351A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
UA99074043A UA57763C2 (uk) 1997-01-20 1998-01-13 Суха порошкова композиція, яка містить формотерол, спосіб її виготовлення та спосіб лікування
JP53421798A JP4512203B2 (ja) 1997-01-20 1998-01-13 フォルモテロールを含む０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤
IDW990665A ID21917A (id) 1997-01-20 1998-01-13 Formulasi untuk inhalasi yang memiliki densitas ruah terlimpah antara 0,28 sampai 038 g/ml dan mengandung formoterol
AU57858/98A AU728835B2 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
EEP199900294A EE04038B1 (et) 1997-01-20 1998-01-13 Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
IL16286498A IL162864A (en) 1997-01-20 1998-01-13 Formulation for inhalation having a poured bulk density of from 0.28 to 0.38g/ml, comprising formoterol
TR1999/01692T TR199901692T2 (xx) 1997-01-20 1998-01-13 Formoterol i�eren yeni solunum form�lasyonu.
ES98901617T ES2212262T3 (es) 1997-01-20 1998-01-13 Nueva formulacion para inhalacion que tiene una densidad aparante de vertido de 0,28 a 0,38 g/ml, que comprende formoterol.
AT98901617T ATE257699T1 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
EP98901617A EP1009394B1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
HU0000843A HU228682B1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising formoterol, its preparation and its use
DE69821119T DE69821119T2 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
NZ336593A NZ336593A (en) 1997-01-20 1998-01-13 Formulation comprising finely divided formoterol and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch
KR10-1999-7006413A KR100528417B1 (ko) 1997-01-20 1998-01-13 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 포르모테롤 함유 신규 흡입 제제
PT98901617T PT1009394E (pt) 1997-01-20 1998-01-13 Nova formulacao para inalacao possuindo uma densidade de po em bruto de desde 0,28 a 0,38 g/ml contendo formoterol
CZ19992556A CZ295682B6 (cs) 1997-01-20 1998-01-13 Suchý práškový prostředek s obsahem formoterolu, způsob jeho přípravy a léčivo s jeho obsahem
CA002277890A CA2277890C (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
PL98334528A PL189552B1 (pl) 1997-01-20 1998-01-13 Sucha kompozycja proszkowa do inhalacji, sposób jej wytwarzania oraz zastosowania tej kompozycji dowytwarzania leku
GR980100022A GR980100022A (el) 1997-01-20 1998-01-14 Νεα συνθεση για εισπνοη
BE9800031A BE1011401A3 (fr) 1997-01-20 1998-01-15 Nouvelle composition pour inhalation.
IE980025A IE980025A1 (en) 1997-01-20 1998-01-16 New formulation for inhalation
FR9800459A FR2759907B1 (fr) 1997-01-20 1998-01-16 Nouvelle composition pour inhalation
ES009800079A ES2149082B1 (es) 1997-01-20 1998-01-16 Nueva formulacion para inhalacion.
IS5109A IS2243B (is) 1997-01-20 1999-07-06 Ný efnablanda til innöndunar sem er með lausþéttniflæði frá 0,28 til 0,38 g/ml, sem inniheldur formóteról
NO19993538A NO327457B1 (no) 1997-01-20 1999-07-19 Torrpulverpreparat som omfatter formoterol samt fremgangsmate for dets fremstilling
US09/401,592 US6199607B1 (en) 1997-01-20 1999-09-22 Formulation for inhalation
JP2009255061A JP2010059180A (ja) 1997-01-20 2009-11-06 フォルモテロールを含む０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700134A SE9700134D0 (sv) 1997-01-20 1997-01-20 New formulation

Publications (1)

Publication Number Publication Date
SE9700134D0 true SE9700134D0 (sv) 1997-01-20

Family

ID=20405453

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700134A SE9700134D0 (sv) 1994-10-03 1997-01-20 New formulation

Country Status (32)

Country Link
EP (1) EP1009394B1 (xx)
JP (2) JP4512203B2 (xx)
KR (1) KR100528417B1 (xx)
CN (1) CN1213741C (xx)
AT (1) ATE257699T1 (xx)
AU (1) AU728835B2 (xx)
BE (1) BE1011401A3 (xx)
BR (1) BR9806895A (xx)
CA (1) CA2277890C (xx)
CZ (1) CZ295682B6 (xx)
DE (1) DE69821119T2 (xx)
DK (1) DK1009394T3 (xx)
EE (1) EE04038B1 (xx)
ES (2) ES2212262T3 (xx)
FR (1) FR2759907B1 (xx)
GR (1) GR980100022A (xx)
HU (1) HU228682B1 (xx)
ID (1) ID21917A (xx)
IE (1) IE980025A1 (xx)
IL (1) IL130837A0 (xx)
IS (1) IS2243B (xx)
NL (1) NL1008021C2 (xx)
NO (1) NO327457B1 (xx)
NZ (1) NZ336593A (xx)
PL (1) PL189552B1 (xx)
PT (1) PT1009394E (xx)
RU (1) RU2180220C2 (xx)
SE (1) SE9700134D0 (xx)
SK (1) SK283949B6 (xx)
TR (1) TR199901692T2 (xx)
UA (1) UA57763C2 (xx)
WO (1) WO1998031351A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
EP2821061B1 (en) 2013-07-01 2017-12-20 Arven Ilac Sanayi Ve Ticaret A.S. Novel inhalation formulations
WO2015060743A1 (ru) * 2013-10-21 2015-04-30 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
KR20220066906A (ko) 2019-09-24 2022-05-24 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제를 위한 신규 담체 입자

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
BR9407686A (pt) * 1993-10-01 1997-02-04 Astra Ab Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
CZ255699A3 (cs) 1999-10-13
CN1213741C (zh) 2005-08-10
HU228682B1 (en) 2013-05-28
FR2759907B1 (fr) 2001-03-09
CA2277890A1 (en) 1998-07-23
JP2010059180A (ja) 2010-03-18
ES2149082A1 (es) 2000-10-16
EP1009394A1 (en) 2000-06-21
ES2212262T3 (es) 2004-07-16
ATE257699T1 (de) 2004-01-15
DE69821119D1 (de) 2004-02-19
KR100528417B1 (ko) 2005-11-16
IL130837A0 (en) 2001-01-28
UA57763C2 (uk) 2003-07-15
WO1998031351A1 (en) 1998-07-23
TR199901692T2 (xx) 1999-09-21
NZ336593A (en) 2001-01-26
RU2180220C2 (ru) 2002-03-10
EP1009394B1 (en) 2004-01-14
GR980100022A (el) 1998-09-30
NL1008021A1 (nl) 1998-07-22
PL334528A1 (en) 2000-02-28
CZ295682B6 (cs) 2005-09-14
NO327457B1 (no) 2009-07-06
JP2001508792A (ja) 2001-07-03
IS2243B (is) 2007-05-15
IE980025A1 (en) 1998-10-07
PT1009394E (pt) 2004-05-31
NL1008021C2 (nl) 1998-10-07
KR20000070187A (ko) 2000-11-25
PL189552B1 (pl) 2005-08-31
DK1009394T3 (da) 2004-04-05
ID21917A (id) 1999-08-12
IS5109A (is) 1999-07-06
BR9806895A (pt) 2000-05-16
EE04038B1 (et) 2003-06-16
CN1243435A (zh) 2000-02-02
NO993538D0 (no) 1999-07-19
SK283949B6 (sk) 2004-05-04
HUP0000843A2 (hu) 2000-09-28
CA2277890C (en) 2006-08-29
BE1011401A3 (fr) 1999-08-03
HUP0000843A3 (en) 2000-10-30
EE9900294A (et) 2000-02-15
AU728835B2 (en) 2001-01-18
AU5785898A (en) 1998-08-07
FR2759907A1 (fr) 1998-08-28
ES2149082B1 (es) 2001-05-16
DE69821119T2 (de) 2004-08-19
JP4512203B2 (ja) 2010-07-28
NO993538L (no) 1999-09-17
SK95899A3 (en) 2000-01-18

Similar Documents

Publication Publication Date Title
SE9700135D0 (sv) New formulation
SE9700133D0 (sv) New formulation
SE9700134D0 (sv) New formulation
SE9700136D0 (sv) New formulation